|Corporis Medical, a medical device company located at the Brightlands Maastricht Health Campus, has formed a consortium with AIM BV (Netherlands), and CSEM SA (Switzerland) to further develop its Perfusion Measurement technology towards a commercial device. The consortium has been recently awarded a EUROSTAR grant for their combined development project.
The project titled “PREV-ALE” aims to further develop an Anastomotic Perfusion Measurement Device (APM) which, during surgery, will be able to measure tissue healing capability. The technology allows already during surgery to predict the risk of ischemic tissue and with that the risk of anastomotic leakage (AL) after surgery. We believe that this will change the surgical field by improving safety and efficacy, whilst reducing complications and costs.
During the two years' grant period, each partner of this multidisciplinary consortium will contribute its expertise to reach their shared goal. Corporis Medical, the inventor of the APM technology will contribute its clinical research and design competences. AIM, an independent contract manufacturer in medical devices and instruments will contribute to building prototypes for testing. CSEM, a private research and technology organization will contribute its expertise and competenciesin microtechnology, sensor technology and electronics.
John Marugg, CEO of Corporis Medical, comments “This consortium will allow us to bring all required competences together needed to further develop, test and manufacture the commercial device. The reviewers of our EUROSTAR grant application were all very excited about the technology and the impact it could have on reducing AL and saving lives.”
Alexander Veenhof, CSO of Corporis Medical and gastrointestinal surgeon; “finally we will be able to locate the optimum location for a new anastomosis during bowel surgery and subsequently prevent many leakages from occurring.”